ADA-SCID
4 Sept 2026 · 6 min read

On this page9 sections
Adenosine Deaminase Deficiency Severe Combined Immunodeficiency (ADA-SCID) is a very rare, inherited genetic disorder that a child is born with. Though rare, it is an exceptionally serious and life-threatening condition.
The disease occurs because the body lacks a crucial enzyme called adenosine deaminase (ADA). Normally, this enzyme is responsible for breaking down and clearing out harmful toxins inside the body's cells.
Impact on the Immune System
Without the ADA enzyme, toxic byproducts rapidly build up and destroy white blood cells (lymphocytes), leaving the baby with a severely compromised and weak immune system. Because their bodies cannot fight off invading pathogens, common everyday infections that healthy infants easily overcome can become life-threatening for a baby with ADA-SCID.
Diagnosing ADA-SCID
When a baby is around 5 days old, they are routinely offered a heel prick screening test to check for ADA-SCID. This quick procedure involves pricking the infant's heel to collect a few drops of blood onto a special card for laboratory testing.
If a baby is diagnosed with ADA-SCID, they face a very high risk of developing severe, life-threatening infections and other major health complications. However, these dangerous risks can be successfully avoided if the condition is caught early through screening and the correct medical treatments are started immediately.
Symptoms of ADA-SCID
Because the adenosine deaminase (ADA) enzyme is needed by cells throughout the entire body, ADA-SCID is a systemic metabolic disorder. This means it causes both immune system failures and non-immune physical symptoms.
The symptoms typically progress and change based on the child's age:
Early Symptoms (In Babies Under 6 Months)
During the first few months of life, symptoms are primarily driven by a rapidly collapsing immune system and abnormal cellular toxic build-ups:
Frequent, Severe Infections: Infants suffer from persistent, life-threatening infections—such as chronic diarrhoea or severe pneumonia—often caused by everyday germs that wouldn't make a healthy baby sick.
Failure to Thrive: The baby will experience significantly slower physical growth and weight gain compared to other children.
Breathing Difficulties: Respiratory distress and rapid breathing can occur, sometimes even without an active lung infection.
Skeletal and Bone Issues: Cellular toxins directly alter bone development. This can cause distinct structural abnormalities, such as unusual, flared rib-ends that show up clearly on a chest X-ray.
Later Symptoms (As Children Grow Older)
If the condition is not successfully treated early on, the ongoing accumulation of toxic byproducts begins to permanently damage other major organ systems:
Neurological Delays: Slower development of the central nervous system, which can cause movement disorders and decreased muscle tone.
Hearing Loss: Some children may experience progressive sensorineural deafness over time as toxins damage the inner ear structures.
Learning and Behavioural Difficulties: Cognitive delays, attention issues, and distinct behavioural struggles can manifest as the brain is affected.
Systemic Organ Damage: Chronic, metabolic poisoning can lead to structural and functional problems in vital internal organs, including the liver, kidneys, and lungs.
Treating ADA-SCID
Treating Adenosine Deaminase Deficiency Severe Combined Immunodeficiency (ADA-SCID) requires a multi-stage approach. Because the condition is a medical emergency, initial treatment focuses on stabilizing the child’s body and providing immediate protection from germs, while definitive long-term cures are prepared.
Stage 1: Immediate Stabilization (The "Bridge" Treatment)
As soon as a baby is diagnosed, doctors initiate Enzyme Replacement Therapy (ERT), typically using a medication like pegylated bovine ADA.
How it works: It replaces the missing ADA enzyme through regular injections. This clears out the cellular toxins and allows the baby’s immune system to gradually start functioning.
The Goal: ERT is not a permanent cure. It serves as a vital stabilizing "bridge" to keep the child safe and infection-free for a few weeks or months while long-term options are arranged.
Stage 2: Protective Medical Care
While awaiting a definitive cure, the infant is kept under strict isolation protocols and given supportive medical therapies to prevent life-threatening illnesses:
Antibiotics and Antivirals: Daily preventative medications to stop opportunistic infections from taking hold.
Immunoglobulin Replacement Therapy: Regular infusions of donor antibodies to give the baby passive immune protection.
Stage 3: Long-Term Curative Options (Requires Traveling Abroad)
Because ADA-SCID is an exceptionally rare condition, highly specialized curative therapies are concentrated in a few elite international medical centers. Patients living in countries like Ireland or the UK typically must travel abroad to access these procedures. State healthcare programs often help fund this cross-border care via initiatives like the HSE Treatment Abroad Scheme.
There are two primary curative paths:
Curative Treatment | How It Works | Major Benefits & Risks |
|---|---|---|
Haematopoietic Stem Cell Transplantation (HSCT) | Replaces the child's faulty immune cells with healthy blood-forming stem cells from a donor (ideally a tissue-matched sibling). | Benefit: Time-tested, highly effective cure. |
Gene Therapy | Doctors harvest the baby's own stem cells, insert a working copy of the ADA gene into them in a laboratory, and infuse them back. | Benefit: Uses the baby's own cells, meaning there is zero risk of donor rejection or GvHD. Specialized European centers (like the San Raffaele Hospital in Milan) perform this. |
How ADA-SCID is inherited
At its core, ADA-SCID is driven by specific genetic mutations in the ADA gene, which completely halt or severely restrict the production of the adenosine deaminase enzyme.
Enzymes are specialized proteins that act as biological catalysts to speed up vital chemical reactions. Without enough of the ADA enzyme, the body cannot execute its natural metabolic recycling process, causing a highly dangerous, toxic substance called deoxyadenosine to build up rapidly inside cells.
The Biological Impact of Deoxyadenosine Build-up
The accumulation of deoxyadenosine is metabolic poisoning. It primarily strikes the cells that are meant to protect the child:
Stops Cell Division: The toxin halts the normal replication and division of cells.
Destroys White Blood Cells: It is uniquely toxic to developing T cells, B cells, and NK cells (lymphocytes).
Collapses the Immune System: Without these critical white blood cells, the body loses its entire defense framework, leaving it utterly unable to fight off everyday infections.
ADA-SCID is an autosomal recessive genetic condition. This means a child only develops the disorder if they inherit two copies of the mutated gene—one from each parent.
[Carrier Father (Aa)] x [Carrier Mother (Aa)]
│
┌─────────────────────────┼─────────────────────────┐
▼ ▼ ▼
[Healthy Child (AA)] [Carrier Child (Aa)] [Affected Child (aa)]
25% Chance 50% Chance 25% Chance
The Parents: Both parents are typically healthy, unaffected carriers who have no symptoms. They carry one mutated copy of the gene (a) and one normal, working copy (A).
The Odds per Pregnancy: Every time two carrier parents have a child, there is a distinct genetic roll of the dice:
A 1 in 4 (25%) chance that the child will inherit both mutated genes and be born with ADA-SCID.
A 2 in 4 (50%) chance that the child will inherit one mutated gene and become a healthy carrier, just like their parents.
A 1 in 4 (25%) chance that the child will inherit two normal genes and be completely clear of the mutation.
